Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03496805 | Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy | completed | Phase 2 | 106 | Wake Forest University Health SciencesOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03947151 | Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer(DEGASTIM) | completed | Phase 2 | 8 | Assistance Publique - Hôpitaux de ParisOTHER |
| 1 |
| Mar 31, 2026 |
| clinicaltrials |
| NCT04677595 | Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-C) | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04339101 | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | completed | Phase 2 | 59 | City of Hope Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05068752 | Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer | completed | Phase 2 | 10 | HonorHealth Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05586516 | A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 16 | iOncturaINDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT00066443 | Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer | completed | Phase 1 / Phase 2 | 93 | NCIC Clinical Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT00428142 | Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 95 | NCIC Clinical Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT00512304 | Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE)(TRACE) | completed | Phase 2 | 63 | University Hospital, RouenOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03328026 | Combination Study of SV-BR-1-GM With Retifanlimab | completed | Phase 1 / Phase 2 | 36 | BriaCell Therapeutics CorporationINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03620019 | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | completed | Phase 2 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04351256 | Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy(TRADE-hypo) | completed | Phase 2 | 51 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04785820 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 18 | Mar 27, 2026 | clinicaltrials |
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme(DENDR1) | completed | Phase 1 / Phase 2 | 76 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05226117 | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | completed | Phase 2 | 44 | IRCCS San RaffaeleOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05376241 | Promoting Informed Choice for Breast Cancer Screening | completed | Phase 2 | 637 | University of Colorado, DenverOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02360579 | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma(LN-144) | completed | Phase 2 | 220 | Iovance Biotherapeutics, Inc.INDUSTRY | 8 | Mar 25, 2026 | clinicaltrials |
| NCT03601923 | Niraparib in Patients With Pancreatic Cancer | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05039177 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies(HERKULES-3) | completed | Phase 1 / Phase 2 | 101 | Erasca, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05068440 | Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib | completed | Phase 2 | 65 | BeiGeneINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493486 | IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study | completed | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT00576979 | Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 51 | City of Hope Medical CenterOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT02723721 | Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face(PICAMEL) | completed | Phase 2 | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03617679 | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | completed | Phase 2 | 79 | University of Colorado, DenverOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03915951 | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | completed | Phase 2 | 98 | PfizerINDUSTRY | 5 | Mar 24, 2026 | clinicaltrials |
| NCT04107727 | Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | completed | Phase 2 | 273 | PETHEMA FoundationOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04484142 | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | completed | Phase 2 | 137 | Daiichi SankyoINDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT04661943 | Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma | completed | Phase 2 | 30 | Ou Bai, MD/PHDOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03217188 | Proton Re-Irradiation for Recurrent Head and Neck Cancer | completed | Phase 2 | 87 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03753659 | IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 30 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04539938 | A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer(HER2CLIMB-04) | completed | Phase 2 | 70 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05963997 | A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer(SUMIT-ELA) | completed | Phase 1 / Phase 2 | 49 | Carrick Therapeutics LimitedINDUSTRY | 4 | Mar 23, 2026 | clinicaltrials |
| NCT02690558 | Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy | completed | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04417088 | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | completed | Phase 1 / Phase 2 | 28 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT01011920 | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | completed | Phase 2 | 227 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 5 | Mar 19, 2026 | clinicaltrials |
| NCT01315132 | A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies | completed | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03709446 | Leflunomide in Previously Treated Metastatic Triple Negative Cancers | completed | Phase 1 / Phase 2 | 17 | Joseph SparanoOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05046314 | A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma | completed | Phase 2 | 15 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05361668 | Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | completed | Phase 2 | 36 | Crinetics Pharmaceuticals Inc.INDUSTRY | 7 | Mar 19, 2026 | clinicaltrials |
| NCT05659563 | Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%(EMPRESS) | completed | Phase 2 | 92 | MedSIROTHER | 2 | Mar 19, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT02601313 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)(ZUMA-2) | completed | Phase 2 | 105 | Kite, A Gilead CompanyINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT03441958 | ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03793361 | Phase II Study of Regorafenib as Maintenance Therapy(EREMISS) | completed | Phase 2 | 127 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04251949 | Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis.(MuciLight) | completed | Phase 2 | 28 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04814108 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | completed | Phase 2 | 92 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT04883281 | A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer(DARTBOARD) | completed | Phase 2 | 50 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 117 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT01612351 | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | completed | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 17, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 31, 2026source: clinicaltrials